articleThe LancetDec 13, 2016GREEN OA

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

ARAchim RittmeyerFBFabrice BarlésiDWDaniel WaterkampKPKeunchil ParkFCFortunato Ciardiello

Aix-Marseille Université · Assistance Publique Hôpitaux de Marseille · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

4,758
total citations
FWCI
232.36
Percentile
100%
References
23
Citations per year

Authors

25

Topics & keywords

Topics
Keywords
  • Medicine
  • Atezolizumab
  • Docetaxel
  • Internal medicine
  • Oncology
  • Lung cancer
  • Population
  • Cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding